评估五种SARS-CoV-2抗体的多重检测方法
该研究评估了多重D-tek COVIDOT 5 IgG检测法对SARS-CoV-2 IgG抗体(N、S1+S2、S1、S2和RBD)的检测性能。在46例经rRT-PCR确诊的COVID-19患者的218份样本中,症状出现14天前敏感性欠佳,≥21天时N、S1+S2、S2和RBD导向IgG敏感性达100%(93.4-100%),S1导向IgG为96.3%(87.3-99.6%)。特异性方面,S1+S2、S2和RBD为100%,N为98.3%,S1为92.4%(86.0-96.5%)。结论认为≥21天敏感性和特异性极佳,但解读单一S1导向反应性需谨慎,多重检测符合CDC的正交检测算法。
要点
- 症状出现14天前敏感性欠佳,≥21天时多数抗体敏感性达100%。
- S1导向IgG特异性较低(92.4%),解读单一S1反应性需谨慎。
- 多重检测符合CDC正交检测算法,有助于更好解读血清学状态。
核心结论
- ≥21天时N、S1+S2、S2和RBD导向IgG敏感性和特异性极佳。
- 解读单一S1导向反应性需谨慎。
- 多重检测符合CDC正交检测算法,可更好解读患者血清学状态。
研究设计与样本
- 评估多重D-tek COVIDOT 5 IgG检测法对SARS-CoV-2 IgG抗体(N、S1+S2、S1、S2和RBD)的检测性能。
- 敏感性评估纳入46例rRT-PCR确诊COVID-19患者的218份样本。
- 特异性分析纳入118份COVID-19大流行前收集的非SARS-CoV-2血清。
主要发现
- 所有IgG抗体自症状出现起呈逐渐动态趋势。
- 症状出现14天前敏感性欠佳。
- ≥21天时N、S1+S2、S2和RBD导向IgG敏感性达100%(93.4-100%),S1导向IgG为96.3%(87.3-99.6%)。
- 46例患者中42例(91.3%)在≥14天时检测到全部五种抗体,其余4例在最大随访期有2至4种抗体阳性。
- 特异性:S1+S2、S2和RBD为100%,N为98.3%,S1为92.4%(86.0-96.5%)。
关键数值与推荐
- ≥21天敏感性:N、S1+S2、S2和RBD导向IgG为100%(93.4-100%),S1导向IgG为96.3%(87.3-99.6%)。
- 特异性:S1+S2、S2和RBD为100%,N为98.3%,S1为92.4%(86.0-96.5%)。
临床怎么用
- 建议在症状出现≥21天时使用该多重检测以获得最佳敏感性。
- 解读单一S1导向反应性时应谨慎,结合其他抗原结果综合判断。
- 多重检测联合使用抗原可提高早期敏感性并保持高特异性,符合CDC正交检测算法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Accurate SARS-CoV-2 serological assays are urgently needed to help diagnose infection, determine past exposure of populations and assess the response to future vaccines. The study aims at assessing the performance of the multiplex D-tek COVIDOT 5 IgG assay for the detection of SARS-CoV-2 IgG antibodies (N, S1+S2, S1, S2 and RBD). METHODS: Sensitivity and dynamic trend to seropositivity were evaluated in 218 samples obtained from 46 rRT-PCR confirmed COVID-19 patients. Non-SARS-CoV-2 sera (n=118) collected before the COVID-19 pandemic with a potential cross-reaction to the SARS-CoV-2 immunoassay were included in the specificity analysis. RESULTS: A gradual dynamic trend since symptom onset was observed for all IgG antibodies. Sensitivities before day 14 were suboptimal. At ≥21 days, sensitivities reached 100% (93.4-100%) for N, S1+S2, S2 and RBD-directed IgG and 96.3% (87.3-99.6%) for S1-directed IgG. In 42 out of 46 patients (91.3%), all five antibodies were detected at ≥14 days. The four remaining patients had between 2 and 4 positive antibodies at their respective maximal follow-up period. The specificity was 100 % for S1+S2, S2 and RBD, 98.3% for N and 92.4% (86.0-96.5%) for S1-directed IgG. The combined use of antigens increases the early sensitivity whilst enforcing high specificity. CONCLUSIONS: Sensitivities at ≥21 days and specificities were excellent, especially for N, S1+S2, S2 and RBD-directed IgG. Caution is however required when interpreting single S1-directed reactivities. Using a multiplex assay complies with the orthogonal testing algorithm of the CDC and allows a better and critical interpretation of the serological status of a patient.
引用
- Favresse J, Brauner J, Bodart N, et al. An original multiplex method to assess five different SARS-CoV-2 antibodies. Clin Chem Lab Med. 2020. PMID: 33554567. doi:10.1515/cclm-2020-1652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。